STOCK TITAN

Evotec Ag - EVO STOCK NEWS

Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.

About Evotec AG

Evotec AG (symbol: EVO) is a globally recognized life sciences company that excels in drug discovery and development, delivering comprehensive solutions for pharmaceutical, biotechnology, and academic partners. With a highly synergistic multimodality platform, Evotec integrates advanced technologies, robust data analytics, and innovative scientific approaches to facilitate the discovery, development, and production of both first-in-class and best-in-class therapeutics.

Comprehensive Business Model

Evotec operates through a unique business model characterized by:

  • Shared R&D Services: Providing tailored drug discovery and manufacturing services on a fee-for-service basis, this segment forms the core of their operations and fuels a significant portion of their revenues.
  • Collaborative Partnerships: Engaging in co-creation partnerships with Top 20 Pharma companies, over 800 biotechnology firms, academic institutions, and nonprofit organizations, Evotec extends its reach across a broad spectrum of therapeutic areas.
  • CDMO and Biologics: Through its Just-Evotec Biologics segment, the company offers specialized contract development and manufacturing operations, particularly in the biologics arena, ensuring high-quality production capabilities.

This diversified model emphasizes strategic alliances, allowing the company to efficiently bridge academic research and commercial development, thereby accelerating the path from bench to bedside.

Innovative Therapeutic Focus

Evotec is renowned for its dedication to addressing unmet medical needs across a variety of therapeutic areas. Key focus areas include:

  • Central nervous system disorders
  • Oncology and metabolic diseases
  • Inflammation and infectious diseases
  • Women's health
  • Emerging areas such as stem cell-based therapies and precision medicine

Each area is supported by a robust research and development structure, where Evotec leverages proprietary assets alongside collaborative research initiatives to push the boundaries of modern medicine.

Global Operational Footprint

Headquartered in Hamburg, Germany, Evotec maintains a strong global presence with production and R&D sites strategically located across Europe and the United States. This international network not only enhances efficiency in operations but also ensures the company can tap into diverse scientific expertise and market dynamics.

Commitment to Excellence and Expertise

Evotec's commitment to quality and innovation is mirrored by its extensive portfolio of co-owned and proprietary research projects, spanning the full spectrum of drug development — from early discovery through to clinical development. By fostering an environment of collaborative excellence and incorporating state-of-the-art technologies, the company continuously reinforces its standing in the competitive pharmaceutical services sector.

Position within the Competitive Landscape

In an industry where precision and innovation are paramount, Evotec distinguishes itself through its integrated approach and proven track record of successful partnerships. The company’s ability to adapt its service offerings to meet evolving client needs and cutting-edge scientific challenges positions it as a formidable partner for stakeholders across the biopharmaceutical spectrum. Its operational excellence and commitment to groundbreaking research underscore a strategic focus on delivering high-quality therapeutic solutions without speculative projections or promotional language.

Conclusion

Evotec AG exemplifies a well-structured, innovative, and collaborative approach to advancing pharmaceutical research. Its robust service offerings, global presence, and diversified therapeutic portfolio provide invaluable insights for investors seeking to understand the dynamics of the life sciences sector. By maintaining a clear focus on strategic R&D initiatives and forming key alliances, Evotec continues to drive progress in the field of drug discovery and development.

Rhea-AI Summary
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ:EVO) announced 14% revenue growth to € 580.1 m in the first nine months of 2023, driven by strong demand and pipeline progress. Despite a cyber-incident costing € 43.9 m, adjusted Group EBITDA increased by 13% to € 50.2 m. The company also reported multiple new drug discovery agreements, co-owned pipeline progress, and a corporate update on its environmental initiatives. The business outlook for full-year 2023 and mid-term goals for 2025 were confirmed, with a focus on revenue growth and emission reduction targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
none
-
Rhea-AI Summary
Evotec SE and Dewpoint Therapeutics have announced a strategic R&D collaboration to advance Dewpoint's oncology pipeline programs using Evotec's data-driven platform. The partnership aims to de-risk and accelerate pre-clinical development candidates to first-in-human clinical studies. Evotec will facilitate the rapid development of Dewpoint's assets using its INDiGO platform. The agreement includes a risk-sharing arrangement and milestone and royalty payments based on program success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
partnership
-
Rhea-AI Summary
Evotec SE announces new partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund to advance drug discovery and create new therapeutics companies in Singapore.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
Rhea-AI Summary
Evotec partners with LabCentral, BioLabs, and MBC BioLabs to provide access to its R&D platform for biotech startups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary
Evotec and Novo Nordisk announce LAB eN², a translational drug discovery accelerator focused on cardiometabolic diseases. Four academic institutions, including Harvard University and Mass General Brigham, have already signed on to participate. LAB eN² aims to accelerate the translation of academic ideas into therapeutic product candidates. It will provide funding, scientific expertise, and technology to advance concepts through pre-clinical proof of concept. Successful candidates may be selected for further investment and development by Novo Nordisk. The prevalence of cardiometabolic diseases is increasing, creating a significant need for new therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary
Evotec SE announces financial results for H1 2023, with group revenues increasing by 14% to €383.8m. Adjusted Group EBITDA totaled €26.1m. New alliances and collaborations reflect success of growth strategy. Business outlook for FY 2023 confirmed with revenues expected to be in a range of €750-790m and adjusted Group EBITDA guidance range between €60-80m. Cyber-incident in Q2 temporarily reduced revenue growth. Unpartnered research and development expenses expected to be in a range of €60-70m.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
none
Rhea-AI Summary
Evotec SE to announce financial results for first half-year of 2023 on August 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
partnership
Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has been awarded a contract worth up to $74 million by the U.S. Department of Defense (DOD) to develop monoclonal antibody-based drug prototypes for orthopoxviruses. The contract includes antibody discovery, development, and clinical trial services. Evotec will leverage its technology platform, J.DESIGN, and its pre-clinical and clinical biologics development capabilities to accelerate the development of safe and efficacious medical countermeasures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none

FAQ

What is the current stock price of Evotec (EVO)?

The current stock price of Evotec (EVO) is $3.34 as of April 1, 2025.

What is the market cap of Evotec (EVO)?

The market cap of Evotec (EVO) is approximately 1.2B.

What is Evotec AG's core business model?

Evotec AG operates through a dual approach, offering fee-for-service drug discovery and manufacturing services alongside collaborative partnerships in R&D and biologics CDMO operations.

In which therapeutic areas does Evotec specialize?

The company is active in multiple areas including central nervous system disorders, oncology, metabolic diseases, inflammation, infectious diseases, and emerging fields such as stem cell-based therapies.

How does Evotec generate revenue?

Revenue is largely generated through its shared R&D services on a fee-for-service basis and through contract development and manufacturing, particularly in the biologics sector.

What makes Evotec a significant player in the pharmaceutical services industry?

Evotec’s strength lies in its integrated platform, robust global presence, and strong network of strategic partnerships with major pharmaceutical companies, biotech firms, and academic institutions.

Where is Evotec headquartered and what is its global footprint?

Headquartered in Hamburg, Germany, Evotec has multiple production and research sites across Europe and the United States, ensuring comprehensive global operations.

How does Evotec enhance its R&D capabilities?

The company leverages a combination of internally developed assets and external collaborations to drive innovation, ensuring a robust pipeline from early discovery to clinical development.

What role do strategic partnerships play in Evotec's operations?

Strategic partnerships allow Evotec to co-create innovative therapies and expand its service offerings, enabling efficient translation of scientific research into therapeutic solutions.
Evotec Ag

OTC:EVO

EVO Rankings

EVO Stock Data

1.18B
354.61M
2.52%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg